PMID- 27811452
OWN - NLM
STAT- MEDLINE
DCOM- 20180221
LR  - 20221207
IS  - 1119-3077 (Print)
VI  - 19
IP  - 6
DP  - 2016 Nov-Dec
TI  - Simultaneous control of blood glucose, blood pressure, and lipid among 
      drug-treated Type 2 diabetes patients from Shaanxi province, North-Western China: 
      A multicenter study.
PG  - 784-792
LID - 10.4103/1119-3077.181359 [doi]
AB  - AIM: To investigate the percentage of patients with Type 2 diabetes mellitus 
      (T2DM) who achieved simultaneous control of glycated hemoglobin (HbA1c), blood 
      pressure (BP), and low-density lipoprotein cholesterol (LDL-C) and also to assess 
      its determinants in Shaanxi province, North-Western China. MATERIALS AND METHODS: 
      This cross-sectional survey was conducted between March and June 2012 in six 
      tertiary hospitals across Shaanxi province. Subjects with known T2DM who had at 
      least one antidiabetic medicine were invited. A questionnaire was used to collect 
      basic information and blood samples were drawn for laboratory measurements. 
      Simultaneous control was defined as HbA1c <7%, BP <130/80 mmHg, and LDL-C <2.6 
      mmol/L. RESULTS: A total of 2274 individuals were included, of which 588 
      individuals (25.9%) achieved good glycemic control (HbA1c <7%) and only 102 
      (4.5%) attained simultaneous control. The percentage of individuals (24.2%) 
      achieving simultaneous control increased with less stringent goals (HbA1c <8%, BP 
      <140/90 mmHg, and LDL-C <2.8 mmol/L). In addition, multivariate analyses showed 
      that body mass index of 24-28 kg/m2 (odds ratio [OR]: 0.577, 95% confidence 
      interval [CI]: 0.376-0.886), HbA1c above 8% at diagnosis (pooled OR: 0.392, 95% 
      CI: 0.254-0.531), and insulin treatment (pooled OR: 0.412, 95% CI: 0.225-0.594) 
      were the independent predictors of simultaneous control. CONCLUSION: Simultaneous 
      control among drug-treated Type 2 diabetes patients was amazingly low in 
      North-Western China. Our present study confirmed the gap between guideline and 
      practice and provided evidence of the need for aggressive diabetes management.
FAU - Xu, S
AU  - Xu S
AD  - Department of Endocrinology, Xijing Hospital, Fourth Military Medical University, 
      Xi'an, China.
FAU - Sun, F
AU  - Sun F
AD  - Department of Endocrinology, Xijing Hospital, Fourth Military Medical University, 
      Xi'an, China.
FAU - Xu, W
AU  - Xu W
AD  - Department of Dermatology, Xiangyang Central Hospital, Affiliated Hospital of 
      Hubei University of Arts and Science, Xiangyang, China.
FAU - Jiao, K
AU  - Jiao K
AD  - Department of Endocrinology, Tangdu Hospital, Fourth Military Medical University, 
      Xi'an, China.
FAU - Shi, B
AU  - Shi B
AD  - Department of Endocrinology, First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Xie, X
AU  - Xie X
AD  - Department of Endocrinology, Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Wang, Y
AU  - Wang Y
AD  - Department of Endocrinology, Shaanxi Provincial People's Hospital, Xi'an, China.
FAU - Zhu, M
AU  - Zhu M
AD  - Department of Nutrition, Xi'an Municipal Central Hospital, Xi'an, China.
FAU - Ji, Q
AU  - Ji Q
AD  - Department of Endocrinology, Xijing Hospital, Fourth Military Medical University, 
      Xi'an, China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Niger J Clin Pract
JT  - Nigerian journal of clinical practice
JID - 101150032
RN  - 0 (Blood Glucose)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Glucose/metabolism
MH  - Blood Pressure
MH  - Body Mass Index
MH  - China
MH  - Cholesterol, LDL/metabolism
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/metabolism
MH  - Dyslipidemias/complications/metabolism
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypertension/complications
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Odds Ratio
EDAT- 2016/11/05 06:00
MHDA- 2018/02/22 06:00
CRDT- 2016/11/05 06:00
PHST- 2016/11/05 06:00 [pubmed]
PHST- 2018/02/22 06:00 [medline]
PHST- 2016/11/05 06:00 [entrez]
AID - NigerJClinPract_2016_19_6_784_181359 [pii]
AID - 10.4103/1119-3077.181359 [doi]
PST - ppublish
SO  - Niger J Clin Pract. 2016 Nov-Dec;19(6):784-792. doi: 10.4103/1119-3077.181359.